Subspecialty Haem Onc amp Lymphoma Recruits per 100000 Population 1 MYELOMA 1 st line MYELOMA XI Randomised comparisons of thalidomide lenalidomide bortezomib carfilzomib combinations and maintenance lenalidomide ID: 499038
Download Presentation The PPT/PDF document "Recruitment of cancer patients by LCRN" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Recruitment of cancer patients by LCRN Subspecialty: Haem Onc & Lymphoma Recruits per 100,000 Population
1Slide2Slide3Slide4Slide5Slide6
MYELOMA 1st line
MYELOMA XI
Randomised comparisons of thalidomide, lenalidomide, bortezomib, carfilzomib combinations and maintenance lenalidomide
UHB/NBT/C+G
Cardamon
Carfilzomib/Cyclo/Dex with maintenance carfilzomib in untreated ASCT-eligible patients
In set-up RUH
TEAMM
Randomized, double-blind, phase III trial of levofloxacin vs placebo in newly diagnosed MM requiring therapy
RUH/NBT/Swindon/C+G
Millennium
Ixazomib maintenance vs placebo after induction therapy if not having ASCT.
UHB In set-up RUH/NBT
2
nd
line
MUK5
CCD (cyclo/carfilz/dex) vs CVD (cyclo/bortezomib/dex) as second line therapy
UHB- JB
MUK8
Relapsed disease randomised trial
UHB-JB in set-up
Amyloid
Prothena
Mab against amyloid protein
UHB-JB/JG in set-up
LYMPHOMA
1
st
line
MCL biobank
All patients newly diagnosed with mantle cell lymphoma, whether requiring therapy or not
UHB/NBT/C+G/Taunton
ENRICH
Older MCL R-ibrutinib vs R-chemo (CHOP or bendamustine at investigator’s discretion)
EOI C+G/UHB
Chemo-T
CHOPx6 vs GEM-P x4
Taunton /C+G/Yeovil
ReModL-B
Adding bortezomib to R-CHOP on basis of GEP – closing June 2015
C+G/RUH/Swindon
R2W
FCR vs bortezomib/cyclo/ritux (BCR) in previously untreated Waldenstroms
RUH/Taunton
MAPLE
FL 3b/DLBCL – observational study of molecular profiling ? new agents in future
RUH/Swindon
EBV
Observational study in EBV assoc T-cell/NK malignancies.
Taunton
PACIFICO
R-CVP vs FCR lite in older patients with untreated follicular NHL
Weston/RUH
NCRN 3171
Double-blind RCT ritux vs biosimilar x4 in untreated, low tumour burden FL.
RUH
INCA
Newly diagnosed DLBCL with cardiac contra-indications to anthracycline – IO-R-CVP vs Gem-R-CVP
UHB /NBT/RUH
NHL TYA
Registry study for all NHL diagnosed age 15-29
UHB in set up LL
Relapsed/refractory
LEGEND
Lenalidomide/gemcitabine/methylpred (L-R-Gem) vs R-GEM-P in relapsed/refractory DLBCL
Taunton – S Bolam
ARROVEN
Relapsed/refractory HL or ALCL – observational study
C+G
LYMRIT-37-01
Phase II – Betalutin (CD37 antibody with radio-isotope) in relapsed FL I-IIIA, marginal zone, SLL, lymphoplasmacytic, mantle cell lymphoma
UHB – Matt Beasley
LYMRIT
Betalutin in r/r FL
UHB in set-up MB
LYMRIT
Betalutin in r/r/ DLBCL
UHB in set-up MB
SADAR
Selinexor in r/r DLBCL
C+G in set up
CLL
1
st
line
FLAIR
FCR vs R-ibrutinib aged 18-75. >20% p53 deletion by FISH excluded.
UHB/NBT/RUH/Taunton, in set-up C+G
Rialto
In less fit patients Ofatumumab/chlorambucil vs Ofatumumab/bendamustine, plus idelalisib vs placebo
Weston/RUH/Swindon/C+G/Yeovil
GALACTIC
GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL
NBT- Sophie
Otton
, in set-up RUH/C+GSlide7
ALL 1st line UKALL2011
Newly diagnosed, Ph-ve ALL patients, aged less than 25
UHB – John Moppett
RUH in set-up
UKALL14
Newly diagnosed ALL patients, aged 25-65 (Ph+ve patients aged 19-65 are eligible)
UHB – David Marks
RUH/C+G/Taunton
UKALL60+
Phase 2 study in newly diagnosed patients with ALL aged over 60 (or over 55 unsuitable for UKALL14)
UHB – DM/Taunton
In set-up C+G
GLOBALL
Coagulation in newly diagnosed ALL - observational
UHB - CB
2
nd
line
T
OWER
Blinatumomab vs standard care in relapsed/refractory Ph- ALL
UHB – DM
Leukaemia/MDS
WT1
Phase 1/2 WT1 TCR gene therapy. AMLnot for allograft - 2
nd
CR, or 1
st
CR in poor risk or >60; CML resistant to imatinib+2
nd
gen TKI not suitable for SCT
UHB – DM
AML
1
st
line
AML 18
AML/RAEB-2 patients, usually aged over 60, fit for intensive therapy
UHB-PM / C+G, In set-up RUH
AML 19
Newly diagnosed patients with AML, aged under 60
UHB in set-up –PM/ RUH/Taunton/C+G
AML LI-1
Newly diagnosed AML (not APL) or RAEB-2, not suitable for intensive therapy, aged over 60.
UHB – PM
Swindon/C+G/Yeovil
Cytarabine sens
Observational study in all AML patients – blood or marrow samples required
UHB – PM
APL coag
Pilot study – understanding and managing the coagulopathy in APL
Taunton
WT-1
Gene therapy study for high risk MDS/AML
UHB-RP in set up
2
nd
line
AMBIT
AC-220 vs standard care in patients with first relapse of FLT3-ITD positive AML
UHB – Priyanka Mehta
CML
SPIRIT 3
On hold centrally
UK-TARGET-CML
EOI C+G
Transplant
UK-POSTAGE
Prospective study of 2
nd
line therapy for acute GVHD, can have had up to 3 weeks steroid therapy for GVHD
UHB –JG
FIGARO
AML/MDS patients having RIC allo SCT – randomised comparison of FLAMSA-BU vs standard conditioning
UHB – RP
Pro T4
Prophylactic transfer CD4+ lymphocytes in patients undergoing FMC sib allo for haematological cancer (2:1 randomisation DLI vs none)
UHB – SR
UK haplo
Haplo SCT (RIC or myeloablative)
UHB – RP
Aztec
Azacytidine for GVHD
UHB – RP in set-up
MDS
MDS Bio
Observational study in all patients with MDS/CMML – please consider when performing a marrow biopsy where MDS is a possible diagnosis
UHB – PM, NBT – AW, C+G
Aza-MDS
Azacitidine vs supportive care in patients with transfusion dependent MDS with PLT <75, IPSS score 0-1.0
UHB – Priyanka Mehta
HR-Elastic
REDDS
De-iron
Phase 2 study of deferasirox at early iron loading in transfusion-dependent MDS
Taunton
MDS-010
Non-interventional study of Low/INT-1 MDS patients, transfusion dependent, with isolated 5q-
In set-up RUHSlide8
MPN
Majic
Ruxolitinib vs best care with PV + high risk feature(>60, previous thrombosis, splenomegaly, PLT >1000, DM /↑bp) resistant to/intolerant of OHurea
RUH/Swindon/Taunton/C+G
MPD-RC114
Ruxolitinib in myelofibrosis pre allograft
UHB-JG in set-up
Other
PNH registry
Patients of any age with a diagnosis of PNH, or a detected PNH clone.
UHB – Priyanka Mehta
Brightlight
Young people aged 13-24 with cancer diagnsosi, recruited within 4 months of diagnosis
RUH
InCite
Case-control study of IC haemorrhage in thrombocytopenic haematology patients
RUH
Zoster002
VZV vaccine therapy in ASCT patients
Swindon
Zoster039
VZV vaccine in haematology patients
Swindon
TREATT
Trial to Evaluate Antifibrinolytic Therapy in Thrombocytopenia
UHB – Andrew Mumford
Non-cancer
ITP registry
All patients diagnosed at any time, need consent and 4 extra bottles EDTA blood, PLT <100
UHB – CB/RUH/Taunton.
In set-up NBT/Yeovil
Mole Ix anaemia
UHB – Charlotte Bradbury/ Taunton